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Abstract
Efforts to develop a broadly protective vaccine against the highly pathogenic avian influenza A (HPAI) H5N1 virus have
focused on highly conserved influenza gene products. The viral nucleoprotein (NP) and ion channel matrix protein (M2) are
highly conserved among different strains and various influenza A subtypes. Here, we investigate the relative efficacy of NP
and M2 compared to HA in protecting against HPAI H5N1 virus. In mice, previous studies have shown that vaccination with
NP and M2 in recombinant DNA and/or adenovirus vectors or with adjuvants confers protection against lethal challenge in
the absence of HA. However, we find that the protective efficacy of NP and M2 diminishes as the virulence and dose of the
challenge virus are increased. To explore this question in a model relevant to human disease, ferrets were immunized with
DNA/rAd5 vaccines encoding NP, M2, HA, NP+M2 or HA+NP+M2. Only HA or HA+NP+M2 vaccination conferred protection
against a stringent virus challenge. Therefore, while gene-based vaccination with NP and M2 may provide moderate levels
of protection against low challenge doses, it is insufficient to confer protective immunity against high challenge doses of
H5N1 in ferrets. These immunogens may require combinatorial vaccination with HA, which confers protection even against
very high doses of lethal viral challenge.
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Introduction
Since 1997, the highly pathogenic avian influenza A H5N1 viral
strain has caused severe disease in poultry and wild birds. Although
H5N1 has not spread widely in humans, sporadic infections have
beenseen throughoutcountriesof eastern Asia,the MiddleEast and
Africa. To date, there have been more than 445 confirmed human
casesofH5N1,with263 deaths(59%mortalityrate) reported bythe
World Health Organization (http://www.who.int/csr/disease/
avian_influenza/country/cases_table_2009_12_11/en/index.html).
In almost all cases, those infected with H5N1 had physical contact
with infected birds. While the primary mode of transmission may be
animal-to-human, the concern remains that this virus may evolve
into a strain capable of human-to-human transmission. Vaccination
offers a practical and effective measure for controlling the spread of
this highly pathogenic virus. The threat posed by emerging strains of
influenza is unpredictable and varies among countries, as evidenced
by the recent swine origin H1N1 pandemic, highlighting the need
for improved vaccines that can confer broad protection against
multiple viral strains and various influenza A subtypes.
While the hemagglutinin (HA) surface protein is conventionally
the primary target of strain-specific influenza DNA vaccines,
conserved viral epitopes have the potential to induce immunity
against diverse influenza strains. Two highly conserved influenza
viral proteins, NP and M2, have been widely targeted as possible
broadly protective vaccine candidates [1–9]. The main function of
the nucleoprotein is encapsidation of the viral genome to form a
ribonucleoprotein particle for transcription and packaging. NP
also interacts with other viral proteins (PB1, PB2, and M1) and
cellular proteins (Importin a, F-actin, CRM1/exportin1) for viral
transcription control and nuclear transportation control [10]. M2
is responsible for protein translocation, and is expressed at a high
density in the plasma membrane of infected cells in tetramer
forms. This ion channel protein is also a target for the antiviral
drugs amantidine and rimantadine, which control viral replication
and have been used for influenza prophylaxis and treatment [11].
In mice, DNA/rAd5 vaccination with NP and M2 from the
H1N1 PR/8 strain induced both humoral and cellular immune
responses that protected against lethal H5N1 challenges [12].
However, the mouse model is not ideal for the evaluation of H5N1
infection and vaccines due to differences in HA receptor specificity
and distribution, influenza pathogenicity, as well as clinical
symptomatology [13–17]. Infection in the ferret shows greater
similarity to human infection in terms of anatomical distribution
and disease. Outbred ferrets exhibit severe lethargy, fever, weight
loss, and transient lymphopenia, as well as viral replication in the
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organs after infection with various strains of H5N1 virus. Thus,
this model is widely considered to be more reflective of human
influenza infection [13,18,19]. While we continued to evaluate the
protective efficacy of NP and M2 in the mouse model, we
extended our investigation into the ferret model in this study.
Previous studies have investigated the protective efficacy of these
conserved epitopes against lethal influenza challenge in mice and
ferrets [7,20,21]. DNA vaccination with NP in combination with
M2 formulated with Vaxfectin has been shown to protect mice
against heterosubtypic challenge with H3N2 and H1N1 viruses
[7]. Vaxfectin-formulated DNA vaccine encoding NP+M2
protected mice, but against high challenge doses of H5N1 virus
in ferrets it only delayed time to illness and death [20]. However,
triple prime with rAd boost regimens of NP in combination with
M2 have been shown to protect ferrets against the H5N1 virus,
albeit at a relatively low challenge dose [21]. In this study, we
evaluated protective immunity induced by NP and M2 alone or in
combination with HA in a triple prime, rAd boost regimen against
high dose lethal H5N1 challenge. Initially, we tested the ability of
DNA immunization with HA alone, NP alone, HA+NP, and
HA+NP+M2 to protect against high doses of lethal H5N1
challenge in mice. We then assessed the ability of NP and M2,
alone or in combination, to protect ferrets against a high challenge
dose of lethal H5N1 virus, when delivered in a triple DNA prime,
rAd5 boost regimen. We compared these groups to ferrets
immunized with HA alone or in combination with NP+M2.
Materials and Methods
Immunogen and plasmid construction
Plasmids encoding HA (A/Thailand/1(KAN-1)/2004, Gen-
Bank AY555150), NP (A/Thailand/1(KAN-1)/2004, GenBank
AAV35112 and A/PR/8/34, GenBank AAM75159), and M2
(A/Thailand/1(KAN-1)/2004, GenBank AAV35111) were syn-
thesized using human-preferred codons and constructed in a
CMV/R backbone by GeneArt (Regensburg, Germany) as
previously described [22]. Gene expression was confirmed using
293T (Invitrogen, Carlsbad, CA) transfected cells by Western blot
analysis.
Adenovirus production
Three separate replication-defective rAd serotype 5 vectors
expressing HA (KAN-1), NP (KAN-1), and M2 (KAN-1) genes
were produced as previously described [23]. Briefly, the genes
were inserted into the GV11 adenoviral vector system (GenVec,
Gaithersburg, MD), which is based on human serotype 5 and
contains deletions of the E1 and E4 regions and part of the E3
region, rendering it replication-defective. The vectors used were as
described elsewhere [23,24]. The vector stocks were serially
passaged in complementing mammalian cells (293-ORF6) to
generate high-titer stocks of replication-defective adenoviruses
[25,26]. Absence of replication-competent adenovirus was con-
firmed by product-release assays. Gene expression in A549
(American Type Culture Collection, Manassas, VA) cells was
confirmed by Western blot analysis.
Expression of immunogens in cell culture
Prior to animal immunization, plasmids and adenoviruses
encoding various influenza viral genes were tested for their
expression in 293T and A549 cells. Plasmids encoding HA protein
of A/Thailand/1/KAN-1/2004, NP proteins of A/PR/8/34 and
A/Thailand/1/KAN-1/2004, and M2 protein of A/Thailand/1/
KAN-1/2004 were transferred into 293T cells using the calcium
phosphate-mediated ProFectionH Mammalian Transfection
system (Promega, Madison, WI). Adenoviruses encoding HA
(KAN-1), NP (KAN-1) and M2 (KAN-1) were transfected into
A549 cells for 48 hours followed by a change of media. Cell lysates
were collected 48 hours post-transfection and subjected to
Western blot analysis by mouse monoclonal antibodies against
HA (KAN-1), NP (KAN-1), NP (PR/8), and by ferret anti-serum
raised against M2 (KAN-1). Specific bands of the predicted size of
proteins were detected by comparison to a known vector control.
H5N1 virus production for viral challenge
The highly virulent A/Vietnam/1203/2004 (H5N1) virus,
isolated from a human with a fatal case of influenza [19], was
used in this study. The virus stock was propagated in the allantoic
cavities of 10-day-old embryonated hens’ eggs following incuba-
tion at 37uC for 24 to 29 hours. Allantoic fluid from multiple eggs
was pooled, clarified by centrifugation, divided into aliquots, and
stored at 270uC. The 50% egg infectious dose (EID50) titers were
determined by serial titration of viruses in eggs and calculated by
the Reed and Muench method [27]. The 50% lethal dose (LD50)
was determined as previously described [19]. All research with
HPAI virus was conducted under Biosafety Level 3 containment,
including enhancements required by the U.S. Department of
Agriculture and the Select Agent Program [28].
DNA vaccination and viral challenge of mice
All animal research was conducted under the guidance of the
Centers for Disease Control and Prevention’s Institutional Animal
Care and Use Committee in an animal facility accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care International. Female BALB/c mice, 6–8 weeks old
(Jackson Labs, Bar Harbor, ME), were immunized as previously
described [22] with HA from A/Thailand/1(KAN-1)/2004, NP
from A/PR/8/34, and M2 from A/Thailand/1(KAN-1)/2004.
Briefly, mice (10 animals for each group of HA alone, HA+NP,
and HA+NP+M2; and 5 animals for the NP alone and vector
control) were immunized three times with a total of 15 mg plasmid
DNA in 100 ml of PBS (pH 7.4) intramuscularly at 0, 3, and 6
weeks. For the single HA or NP plasmid group, each group
received 5 mg DNA for each plasmid with 10 mg of control vector
as filler DNA (total 15 mg). For the 2 plasmid combination group
(HA+NP), 5 mg of each plasmid plus 5 mg control vector was used.
For the 3 plasmid combination group (HA+NP+M2), 5 mg of each
plasmid DNA was used as total DNA remained the same (15 mg).
Serum was collected 10 days after the last DNA vaccination.
Viral challenge experiments were performed 3 weeks after the
last immunization. All challenged animals were exposed under
CO2 anesthesia to an intranasal viral inoculum of 100 LD50 of A/
Vietnam/1203/2004 virus. Body weight and survival were
monitored for 21 days. The viral challenge experiments were
conducted at the Centers for Disease Control and Prevention
(Atlanta, GA) as previously described [17].
DNA and rAd5 vaccination and viral challenge of ferrets
Male Fitch ferrets, 6–12 months of age (Triple F Farms, Sayre,
PA), that were serologically negative by hemagglutinin inhibition
(HAI) assay for currently circulating influenza viruses, were used in
thisstudy.All HA, NPand M2genesare from A/Thailand/1(KAN-
1)/2004.Thenumbersofanimalsusedinourstudieswereasfollows:
(a) 4 animals for each group of NP and M2 alone, (b) 5 animals for
the NP+M2 and the negative control group, (c) in another
experiment, 4 animals for all three groups: HA alone, HA+NP+M2
and the vector control. The ferrets were immunized three times
with a total of 250 mgp l a s m i dD N Ai n5 0 0ml of PBS (pH 7.4)
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the single component plasmid group, each animal received 83 mg
DNA for each plasmid with 167 mg of control vector as filler DNA
(total 250 mg). For the 2 plasmid combination group (e.g. NP+M2),
83 mg of each NP and M2 plasmid with 83 mg control vector was
used (total 250 mg). For the 3 plasmid combination group
(HA+NP+M2), 83 mg of each three plasmid DNA was used as total
DNA remained the same (total 250 mg). At week 9, the ferrets were
immunized intramuscularly with 10
10 particles of recombinant
adenoviruses expressing HA, NP, M2, or in different combinations
similar to their DNA immunization combinations. Serum was
collected 10 days after the last vaccination. The DNA and
adenovirus immunizations were conducted at BioQual, Inc. (Rock-
ville, MD). Nine to ten weeks after the adenovirus boost, the
immunized ferrets were challenged with A/Vietnam/1203/2004
virus, which has the identical NP and M2 amino acid sequence as
that of the immunized strain A/Thailand/1(KAN-1)/2004, at the
Centers for Disease Control and Prevention (Atlanta, GA) as
previously described [19]. Briefly, 2 days prior to infection, baseline
serum, body temperature, and weight measurements of the ferrets
were obtained. After the ferrets were anesthetized by an intramus-
cular injection of ketamine hydrochloride (24 mg/kg), xylazine
(2 mg/kg) and atropine (0.05 mg/kg) cocktail, they were inoculated
intranasally with 10
7 EID50 of virus in 1 ml of PBS. The ferrets were
monitored for changes in body temperature and weight and the
presence of the following clinical symptoms: sneezing, lethargy,
anorexia, nasal or ocular discharge, dyspnea, diarrhea, and
neurological dysfunction. Body temperatures were measured using
an implantable subcutaneous temperature transponder (BioMedic
Data Systems,Inc., Seaford,DE).Viral titers were measured innasal
washes collected on days 3, 5, and 7 post-infection from anesthetized
ferrets as previously described [6]. The nasal washes were
immediately frozen on dry ice and stored at 270uCu n t i lt h e yw e r e
processed. Viral titers in the nasal washes were determined in eggs as
described above. Any ferret that lost more than 25% of its body
weight or exhibited neurological dysfunction was euthanized and
submitted to postmortem examination. Body weight, clinical
symptoms, signs of morbidity, and survival were monitored for 7
or up to 13 days. The statistical significance of differences in survival
between groups was determined using a log-rank test.
Enzyme-linked immunosorbent assay measuring
humoral responses of mice and ferret sera
The ELISA assay used in this study was previously described in
detail [22,29,30]. Briefly, ELISA plates were coated with antigens
(100 ml/well) of the following:
(a) for anti-HA titer: purified HA (KAN-1) (1 mg/ml) as
previously described [31],
(b) for anti-NP (PR/8) titer: purified NP (PR8) (1 mg/ml;
Imgenex, San Diego, CA),
(c) for anti-NP (KAN-1) titer: 1:3 dilution of the supernatant of
NP (KAN-1) encoded plasmid transfected 293 cells,
(d) for anti-M2 (KAN-1) titer: the extracellular part of M2
(KAN-1) (SLLTEVETPTRNEWECRCSDSSD) synthetic
peptide (1.0 mg/ml), kindly provided by Suzanne Epstein
at the Food and Drug Administration,
(e) NP (KAN-1) in 1:3 dilution with PBS, isolated from the
supernatant of NP (KAN-1) encoded plasmid transfected
293T cells.
End-point titers were determined by linear regression analysis of
the absorbance values (OD 450) as previously described [32–34],
with R
2.0.9 obtained from a series of three-fold dilutions, as the
cut-off value was set as 0.3.
Microneutralization assay of mouse and ferret sera
A microneutralization assay to detect humoral neutralization
responses against influenza was performed as previously described
[22,35]. For mice, two-fold dilutions of heat-inactivated sera were
tested for the presence of antibodies that neutralized the infectivity
of 100 TCID50 (50% tissue culture infectious dose) of H5N1
viruses on MDCK cell monolayers using two wells per dilution on
a 96-well plate as described [35]. After 2 days of incubation, cells
were fixed, and ELISA was performed to detect the presence of
viral nucleoprotein (NP) and determine the neutralization activity.
For ferrets, neutralizing antibody activity was analyzed in an MN
assay based on the methods of the WHO Global Influenza
Program [36]. Sera were treated with receptor-destroying enzyme
by diluting one part serum with three parts enzyme and incubated
overnight in a 37uC water bath and heat-inactivated as described
for the HAI assay. Virus strains used for the MN assay are low-
pathogenic, H5N1-PR8 re-assortants, obtained from Ruben Donis
at the CDC Influenza Branch (Atlanta, GA): Clade 1, A/
Vietnam/1203/2004(H5N1)/PR8-IBCDC-RG and Clade 2.1,
A/Indo/5/2005(H5N1)/PR8-IBCDC-RG2. Seed stocks of the
re-assortant strains were obtained and expanded at BIOQUAL in
10-day-old embryonated chicken eggs.
Hemagglutination inhibition (HAI) assay of ferret sera
HAI assays were performed using four hemagglutinin units of
virus and 1% horse RBC as previously described [37–40]. Ferret
sera were treated with receptor-destroying enzyme by diluting one
part serum with three parts enzyme and incubated overnight in a
37uC water bath. The enzyme was inactivated by 30 min.
incubation at 56uC followed by addition of six parts PBS for a
final dilution of 1/10. Virus strains used for the HAI assay were
low-pathogenic, H5N1-PR8 re-assortants obtained from Ruben
Donis at the CDC Influenza Branch (Atlanta, GA): Clade 1, A/
Vietnam/1203/2004(H5N1)/PR8-IBCDC-RG and Clade 2.1,
A/Indo/5/2005(H5N1)/PR8-IBCDC-RG2. Seed stocks of the
re-assortant strains were obtained and expanded at BIOQUAL in
10-day-old embryonated chicken eggs. Virus strains used for the
HAI assay were identical to the low pathogenic re-assortants listed
for the MN assay.
Production of pseudotyped lentiviral vectors and
measurement of neutralizing antibodies from mouse and
ferret serum
The recombinantlentiviralvectorsexpressing a luciferasereporter
gene were produced as previously described [22,29,31,41]. This
assay has been developed as a safer, highly sensitive alternative to
HAIandMNassaysthatcanbe appliedinahigh-throughputformat
for influenza vaccine evaluation [42–44]. Briefly, HA-pseudotyped
lentiviral vectors encoding luciferase were first titrated by serial
dilution. The concentration of virus giving 25% maximum activity
was then incubated with the indicated amounts of mouse anti-serum
before being added to 293A cells. Plates were washed and replaced
with fresh media 14–16 hours later. Luciferase activity was
measured after 48 hours as previously described [45] using
mammalian cell lysis buffer and luciferase assay reagent (Promega,
Madison, WI) according to the manufacturer’s protocol.
Statistical analysis
Linear regression was utilized to determine the end-point
titers of the antibodies against different antigens. In addition, the
Genetic Vaccines for H5N1
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test using GraphPad Prism software (San Diego, CA). End-point
antibody titers in log 10 scale of different groups were compared
by one-way Analysis of Variance (ANOVA). If this was significant
at alpha=.05, we proceeded to look at pairwise comparisons using
t-tests. For four or more groups (mice studies), the p-values from
the pairwise tests were compared to a Bonferroni-adjused
threshold of .05/6=.008, where 6 comparisons were being made
between each set of 4 groups with relevant immunogens. For three
groups (ferret studies), we used instead Fisher’s Least Significant
Difference method to maintain a threshold of alpha=.05 for the
pairwise tests following a significant ANOVA.
Results
Immunogen expression in mammalian cells
Prior to animal immunizations, expression of specific influenza
viral genes was confirmed in 293T cells (Figure 1A) or A549 cells
(Figure 1B). Western blot analysis confirmed the expression of HA
protein of A/Thailand/1/KAN-1/2004 (Figure 1A, lane 2), NP
proteinofA/PR/8/34(Figure1A, lane 3) and A/Thailand/1/KAN-
1/2004 (Figure 1A, lane 4), and M2 protein of A/Thailand/1/KAN-
1/2004 (Figure 1A, lane 6) in 293T cells transfected by eukaryotic
plasmid expression vectors. To confirm expression of rAd5 vectors,
A549 cells were analyzed by Western blot analysis after transduction
with vectors encoding HA (KAN-1) (Figure 1B, lane 8), NP (KAN-1)
(Figure 1B, lane 9), and M2 (KAN-1) (Figure 1B, lane 11).
Combinatorial DNA vaccination with HA, NP, and M2
followed by viral challenge in mice
We evaluated different DNA immunogens [HA (KAN-1) alone;
HA (KAN-1) with NP (PR/8); HA (KAN-1) with NP (PR/8) and
M2 (KAN-1); or NP (PR/8)] for their ability to elicit protective
immunity against A/Vietnam/1203/2004 (H5N1) using the
mouse challenge model. Study cohorts consisted of 10 female
BALB/c mice for the HA alone, HA+NP, and HA+NP+M2
groups, and 5 animals for the NP alone and vector control groups.
Serum was collected 10 days after the last DNA vaccination, and
end-point ELISA titers were evaluated after DNA immunization
(Figure 2). All HA-containing groups showed an increase in HA
ELISA titer compared to the control cohort (p,0.0013) (Figure 2,
left panel). As might be expected, these levels appeared to decrease
with the number of gene products in the DNA vaccine, although
significant differences were not observed amongst the HA-
containing groups.
In analyzing antibody responses against NP protein (Figure 2,
middle panel), the result of the ANOVA was a borderline p-value
of 0.0504. Pairwise comparisons between the HA alone and
HA+NP group were similar (p=.0080 with a Bonferroni-adjusted
threshold of .05/6=.0083). However, when analyzing antibody
responses against M2 protein, DNA vaccination with M2 in
combination with both HA and NP elicited a significant humoral
response compared to controls (p,0.0001) (Figure 2, right panel).
This result suggests that M2 is immunogenic, although immuni-
zation with M2 alone was not included in this study.
Figure 1. Expression of immunogens using DNA and rAd5 vectors in cell culture. (A) Western blot analysis confirmed the expression of HA
protein of A/Thailand/1/KAN-1/2004 (lane 2), NP protein of A/PR/8/34 (lane 3) and A/Thailand/1/KAN-1/2004 (lane 4), and M2 protein of A/Thailand/1/
KAN-1/2004 (lane 6) in 293T cells transfected by eukaryotic plasmid expression vectors. (B) Expression of rAd5 vectors was confirmed in A549 cells
after transduction with vectors encoding HA (KAN-1) (lane 8), NP (KAN-1) (lane 9), and M2 (KAN-1) (lane 11). Arrows indicate the relevant predicted
size of the indicated viral proteins. Bands refer to the right predicted size of different viral proteins that were detected in each lane as indicated.
Molecular weight markers were used for protein size reference.
doi:10.1371/journal.pone.0009812.g001
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pooled by groups and pseudotype neutralization, and microneu-
tralization assays were performed. These analyses revealed
neutralization activity in the HA group, with lower titers in
animals immunized with HA+NP and lowest responses in those
vaccinated with HA+NP+M2 (Table 1). However, minimal
neutralization was evident in NP-only immunized animals. HAI
assays were not performed on the mouse sera.
To determine the efficacy of these alternative DNA immuni-
zations, mice were challenged with the HPAI A/Vietnam/1203/
2004 virus. Mice were challenged intranasally with 100 LD50 of
A/Vietnam/1203/2004 virus, providing a stringent evaluation of
protective efficacy. All animals in the control and NP alone groups
died within 6 days after viral challenge, whereas animals
immunized with HA alone, HA+NP and HA+NP+M2 showed
survival rates of 100, 90 and 70%, respectively (Figure 3A); these
survival rates were not statistically significantly different. As
expected, the HA alone group showed the least amount of body
weight loss, while groups HA+NP and HA+NP+M2 showed
similar weight loss patterns (Figure 3B). In contrast, the control
and NP groups that showed no immune protection demonstrated
severe weight loss (Figure 3B). This finding suggests that NP DNA
immunization does not confer protection against H5N1 viral
challenge at the doses used here.
Comparative efficacy of DNA/rAd5 vaccination with
different combinations of HA, NP and M2 in ferrets
To determine the comparative efficacy of alternative gene-based
vaccines in ferrets, we immunized ferrets with these gene products
in different combinations in a triple DNA inmmunization. In this
experiment, animals received a recombinant adenovirus serotype
5 (rAd5) boost in order to increase the immunogenicity of DNA
priming. Ferrets were immunized with HA alone (n=4);
HA+NP+M2 (n=4); NP alone (n=4); NP+M2 (n=5); M2 alone
(n=4); or empty vector controls (n=4+5). ELISA titers to HA, NP
and M2 were determined after DNA immunization (Figure 4,
white bars) and after the rAd5 boost (Figure 4, black bars). As
expected, after DNA immunization, the HA alone group elicited
Figure 2. Detection of humoral immune responses to HA, NP and M2 by ELISA after DNA vaccination in mice. Sera from individual mice
immunized with HA, HA+NP, HA+NP+M2, NP and vector control were collected 10 days after the third DNA immunization. The sera were subjected to
ELISA assay to determine their end-point titers against HA(KAN-1), NP(PR8), and M2 (KAN-1). Each bar represents the group mean (n=5 for NP,
control; n=10 for HA, HA+NP, HA+NP+M2) for the end-point titers of the total IgG and IgM against HA(KAN-1) purified protein (HA), against NP(PR/8)
purified protein (NP), and against M2(KAN-1) extracellular domain peptide (M2), as indicated. Each immunized group was compared to controls as
well as other groups containing relevant immunogens. ANOVA tests were significant for the responses against HA and M2, but not against NP. For HA
and M2, significant pairs of groups are noted on the graph. Only p-values less than 0.05/6=0.0083 (Bonferroni Correction) were considered significant
for these pairwise comparisons. A single asterisk (*) represents a p-value between 0.008 and 0.001, while ** indicates ,0.001, and *** indicates
,0.0001. All HA-containing groups showed significant antibody responses against HA compared to controls (p,0.0013), but did not differ
significantly among themselves. Differences between NP-immunized groups were at the border of statistical significance by ANOVA (p=0.0504), as
was the comparison between HA+NP and HA groups (p=0.008) when adjusted for multiple comparisons. The only M2-containing group, HA+NP+M2,
elicited a significant humoral response against M2 protein compared to control (p,0.0001).
doi:10.1371/journal.pone.0009812.g002
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(Figure 4A, left panel) compared to controls (p,0.0001). The
HA+NP+M2 group elicited similar anti-HA ELISA antibodies, as
well as significant anti-NP humoral responses (p=0.0006) and
anti-M2 responses (p,0.0001) after the rAd boost (Figure 4A,
middle and right panels) when compared to controls. For both NP
and NP+M2 immunized groups, significant anti-NP humoral
responses were observed after the rAd boost (p,0.0001) (Figure 4B,
middle panel) compared to controls. Significant anti-M2 humoral
responses were detected in animals immunized with NP+M2 post-
rAd boost (p=0.0005), but not in the M2 alone group (Figure 4B,
right panel) relative to controls. Anti-M2 humoral responses were
not detectable in most cases, except after DNA/rAd5 immuniza-
tion with M2 in combination with NP.
The ability of the HA antibodies from immunized ferrets to
neutralize H5N1 virus was analyzed with three assays: a
pseudotyped lentiviral vector neutralizing assay, an HA inhibition
assay, and a microneutralization assay (Table 1; Ferrets). Only
HA-containing groups showed substantial neutralizing antibody
titer responses, while NP, M2, and NP+M2 groups showed no
neutralization in each assay.
At least nine weeks after the rAd5 boost, ferrets were challenged
with a high dose of A/Vietnam/1203/2004 (H5N1) virus. All
groups that lacked HA, including NP alone, NP+M2, and M2
alone, developed severe disease, manifested by significant weight
loss and neurological dysfunction less than seven days after the viral
challenge, similar to the clinical symptoms observed in the control
group (Figure 5A, left panel). The animals were euthanized due to
severity of symptoms.The body weightloss among these groups was
very similar (Figure 5B, left panel). In contrast, the HA and
HA+NP+M2 groups were completely protected from lethality after
a high dose of influenza virus challenge compared to no survival in
empty vector immunized controls (Figure 5A, right panel). Three
animals showed very mild clinical signs such as slight temperature
elevationorweight loss three days after the viral challenge,butthese
symptoms disappeared within two days. Body weight of the two
groups remained steady post-viral challenge in HA-immunized
ferrets (Figure 5B, right panel), in contrast to the controls. Viral
titers from the nasal washes confirmed the antiviral effects of HA-
but not NP-containing vaccines (data not shown). Control animals
showed peak viral titers at day 3, and subsequently died by day 6.
Both HA and HA+NP+M2 groups showed moderate viral titers at
day 3, followed by quick clearance with no viral titers detectable at
day 5 and day 7 (data not shown). Survival, body weight, and viral
titers are indistinguishable between the HA and HA+NP+M2
groups after viral challenge, suggesting that the NP and M2 did not
contribute to immune protection in ferrets. HA immune responses
alone were necessary and sufficient to protect ferrets from the lethal
effects of infection under these challenge conditions.
Discussion
The highly conserved viral genes NP and M2 have become a
focus for the development of broad, cross-protective or ‘‘universal’’
influenza vaccines. In mice, several studies have shown that gene-
based immunization with NP and M2 induce strong humoral and
cellular responses, and protect against lethal H5N1 challenges
[1,4,6,9,22,35,46–48]. In this study, mice were immunized with
DNA vaccines encoding HA alone, NP alone, HA+NP, and
HA+NP+M2. All HA-containing groups and the M2-containing
group generated significant antibody responses against HA and
M2 proteins, respectively. However, only the HA+NP group
elicited a response against NP protein, and that was marginally
significant at best. Moreover, while all HA-containing groups were
protected against lethal H5N1 challenge with a survival rate of at
least 70%, immunization with NP alone did not protect mice from
lethal H5N1 challenge (Figure 3).










37 Control vector 0 NA ,20
31 HA 382 NA 80
32 HA+NP 151 NA 40
33 HA+NP+M2 ,100 NA 20
34 NP 0 NA 30
Ferrets
1 Control vector 0 ,20 ,20
2 Control vector 0 ,20 ,20
3 Control vector 0 ,20 ,20
4 Control vector 0 ,20 ,20
5 HA 5691 NA NA
6 HA 1353 1280 640
7 HA 1239 160 80
8 HA 4636 1280 640
9H A +NP+M2 2047 640 320
10 HA+NP+M2 826 640 160
11 HA+NP+M2 4621 1280 320
12 HA+NP+M2 2466 1280 320
13 Control vector UD ,20 ,20
14 Control vector UD ,20 ,20
15 Control vector UD ,20 ,20
16 Control vector UD ,20 ,20
17 Control vector UD ,20 ,20
18 NP UD ,20 ,20
19 NP UD ,20 ,20
20 NP UD ,20 ,20
21 NP UD ,20 ,20
22 NP+M2 UD ,20 ,20
23 NP+M2 UD ,20 ,20
24 NP+M2 UD ,20 ,20
25 NP+M2 UD ,20 ,20
26 NP+M2 UD ,20 ,20
27 M2 UD ,20 ,20
28 M2 UD ,20 ,20
29 M2 UD ,20 ,20
30 M2 UD ,20 ,20
*UD=Undetectable; NA=Not Assessed.
Neutralization was determined by lentiviral inhibition assay, hemagglutinin
inhibition assay, and microneutralization assay. Sera from the indicated mouse
and ferret immunizations with the indicated viral antigens by DNA alone or
DNA/rAd5 before the viral challenge were evaluated by pseudotyped lentiviral
inhibition, hemagglutinin inhibition (HAI), and microneutralization assays (MN).
UD represents serum samples with undetectable neutralization activities even
at the lowest dilutions, while NA represents samples that were not available,
and therefore not assessed. In both mice and ferrets, only HA-containing
groups stimulated strong humoral responses.
doi:10.1371/journal.pone.0009812.t001
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results, likely dependent on the mode of gene-based vaccination
and on the dose of challenge virus. Though the first studies using
NP DNA immunization conferred protection against lethal
influenza challenge [5,48], in retrospect, this result may be seen
with relatively low challenge doses. In a more recent study, a
challenge dose that overcame NP DNA vaccine protection was
similar to the amount used here [2]. NP immunization with DNA/
rAd derived from H1N1 strain A/PR/8 resulted in protection in
mice against challenge with a heterologous virus strain, H5N1 A/
HK/156, but no protection was seen against a more virulent
strain, A/HK/483 [1]. It appears that protection afforded by
immunization with NP in mice diminishes markedly as the
dose and virulence of the challenge virus increase. However, DNA
vaccination with NP in combination with M2 has been shown to
protect mice in both Vaxfectin formulations and rAd-boost
regimens [7,20,21]. While we did not investigate M2 alone in
mice, a previous study has shown that vaccination with M2 alone
is capable of protecting mice against heterologous strains of
influenza virus challenge, including H5N1 [9].
Despite showing no neutralizing antibody responses, mice
immunized with HA+NP+M2 were fully protected against lethal
challenge. Lalor et al. showed a similar result in which a
Vaxfectin-formulated DNA vaccine encoding H5+NP+M2 con-
sensus genes protected mice against H5N1 challenge, despite low
HAI responses. This is suggestive of other useful mechanisms of
protection, such as cytotoxic T-lymphocytes, although this was
not assessed in our study. A previous study with DNA/rAd5
Figure 3. DNA immunization with HA, HA+NP, and HA+NP+M2 induces similar protection after A/Vietnam/1203/2004 virus
challenge in mice. (A) Survival data is shown as a percentage comparing the final animal number at day 21 with the initial animal number in each
group. All HA-containing groups showed significant survival compared to controls. There is no statistical difference between the HA, HA+NP and
HA+NP+M2 groups (p=0.317 between HA and HA+NP; p=0.146 between HA and HA+NP+M2; p=0.515 between HA+NP and HA+NP+M2 by log-
rank test); NP and the control groups were not statistically different from each other. (B) Body weights of the mice were also monitored and the total
body weight of all of the surviving animals in each group was compared with the respective initial body weights. As expected, the HA group showed
the least amount of body weight loss, with the other HA-containing groups showing similar patterns. However, the NP-immunized group
demonstrated severe weight loss, similar to controls.
doi:10.1371/journal.pone.0009812.g003
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9812Figure 4. Humoral immune responses to HA, NP and M2 confirmed by ELISA after DNA/rAd5 immunization in ferrets. (A) Sera from
the HA, HA+NP+M2 or vector control immunized ferrets were collected 14 days after the third DNA immunization (white bars), and 14 days after the
recombinant adenovirus boost (solid bars), and subjected to ELISA assays to determine their end-point titer levels against HA(KAN-1), NP(KAN-1), and
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contribute to protection in this model [12].
While the mouse model has been used for immunogenicity
studies, the murine disease does not have the same pathogenicity
as human infection and is not ideal for H5N1 infection studies.
These differences may be due to species changes in HA receptor
specificity and distribution, as well as differential immunopatho-
genicity [13–17]. In contrast, it is generally accepted that ferrets
exhibit pathology more similar to humans after H5N1 infection,
including severe lethargy, fever, weight loss, transient lymphope-
nia, and viral replication in the upper/lower respiratory tracts and
multiple systemic organs [13]. Furthermore, human isolates of
influenza virus have been shown to attach and infect ferret airways
[49,50], indicating that humans and ferrets share similar HA
receptor specificity [51].
Ferrets were immunized with HA alone, NP alone, M2 alone,
NP+M2, HA+NP+M2, and control using gene-based vaccines
delivered in DNA/rAd5 vectors. Since there are no established
Figure 5. Protection of DNA/rAd5 vaccines encoding HA or HA+NP+M2, but not NP, NP+M2, or M2, against A/Vietnam/1203/2004
virus challenge. (A) Ferrets immunized three times with DNA followed by a single rAd5 boost were challenged under anesthesia with 10
7 EID50/
ferret of influenza virus A/Vietnam/1203/2004. The animals were monitored 7 days for survival, shown as a percentage comparing the initial animal
number to the final animal number in the same group (left panel). There was no statistical difference between the control group and groups
immunized with NP, NP+M2, or M2. Both the HA and HA+NP+M2 groups showed 100% survival (right panel), whereas the vector control group
showed 0% survival after the viral challenge. There was no statistically significant difference between the HA and HA+NP+M2 groups (p=1.00), but
there was a significant difference between these groups and the control (p=0.008), by a log-rank test. (B) Body weights of the ferrets were also
monitored and the total body weight of all of the surviving animals in each group was compared with the respective initial body weight (left panel).
Ferrets immunized with HA and HA+NP+M2 groups showed no weight loss, while the control group ferrets showed rapid weight loss (right panel).
The survival and initial animal numbers in each group on the last day of body weight data collection are indicated next to the curve labels. The
survival percentage for each group was analyzed statistically by a log-rank test.
doi:10.1371/journal.pone.0009812.g005
M2(KAN-1) antigens. Each bar represents the group mean for the end-point titers of total IgG and IgM, determined in duplicate by series dilution of
ELISA assay with the error bars indicating the standard deviation. ANOVA tests were significant for only the responses against HA at the first time
point, and for all three antigens after the rAd5 boost. For HA and M2, significant pairs of groups are noted on the graph. Only p-values less than 0.05
are indicated. * represents a p-value between 0.05 and 0.001, while ** indicates ,0.001, and *** indicates ,0.0001. As expected, the HA alone group
elicited significant anti-HA immunity that increased after rAd5 HA boost (left panel) compared to controls (p,0.0001). The HA+NP+M2 group elicited
similar anti-HA ELISA antibodies, as well as significant anti-NP humoral responses (p=0.0006) and anti-M2 responses (p,0.0001) after the rAd boost
(middle and right panels). (B) Sera from the NP, M2, NP+M2 or vector controls were collected 14 days after the third DNA immunization (white bars),
and the sera from the same animals were also collected 14 days after the recombinant adenovirus boost (solid bars). ANOVA tests were not significant
for any of the antigens at the first time point, and for NP and M2 after the rAd5 boost. For NP and M2, significant pairs of groups are noted on the
graph. Only p-values less than 0.008 are indicated. * represents a p-value between 0.008 and 0.001, while ** indicates ,0.001, and *** indicates
,0.0001. For both NP and NP+M2 immunized groups, significant anti-NP humoral responses were observed after the rAd boost (p,0.0001) (middle
panel). Significant anti-M2 humoral responses were detected in animals immunized with NP+M2 post-rAd boost (p=0.0005), but not in the M2 alone
group (right panel).
doi:10.1371/journal.pone.0009812.g004
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M2 in ferrets, the efficacy of these immunogens was evaluated
based on the measurement of neutralizing antibody titers through
microneutralization and HA-inhibition assays. When HA and NP
were present, significant humoral responses were stimulated
against these proteins. However, M2 antibodies were only
stimulated when M2 was in combination with NP, suggesting
possible immune synergy of the two gene products. Similar
adjuvant effects of NP in the anti-M2 response have recently been
reported in mice [21]. Each group was challenged with a lethal
strain of HPAI H5N1, and only vaccines containing HA conferred
protection while NP, M2, and NP+M2 groups did not survive.
Lalor et al. showed NP+M2 to be protective in mice, but only
when formulated with Vaxfectin and in a vaccine dose 6.6 times
greater than that used in this study. However, in ferrets, in the
absence of HA, this combination only resulted in delayed illness
and death [20]. Price et al. showed that NP+M2 protects ferrets
against H5N1 in a triple-prime rAd boost regimen similar to the
one used here, but this difference in results may be due to the
higher dose of DNA in the primary immunization (ten-fold greater
than the present study) as well as a much lower viral challenge
dose (56LD50 [21] compared to 3610
56LD50 in this study).
However, due to differences in experimental parameters such as
the immunization regimen and assay standardization, direct
comparisons of NP and M2 immune responses between studies
are difficult. In addition, different vaccinations may alter various
antibody and cellular immune responses which may affect the
protective immunity in various animal models. Nonetheless, the
evidence suggests while NP or NP+M2 may provide moderate
levels of protection against low dose viral challenges in ferrets, they
are insufficient against high challenge doses of HPAI. On the other
hand, HA elicits effective immune protection even against very
high HPAI viral challenge doses. Although vaccines encoding NP
or M2 alone are not required for protection against H5N1, they
could potentially augment HA-encoded vaccines, particularly
when there is a mismatch between the vaccine and viral HA
proteins. Studies in mice have shown that M2 antibodies may help
to reduce viral replication [8,9,52,53], while studies in ferrets have
shown M2 to be associated with reductions in viral recovery
[20,54]. However, based on our H5N1 challenge results in ferrets,
HA DNA immunization is superior to NP and M2 DNA
immunization in terms of protection. These highly conserved
viral genes may require combinatorial vaccination with HA to be
suitable candidates for universal influenza vaccines.
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